Profile data is unavailable for this security.
About the company
Oruka Therapeutics, Inc., formerly ARCA biopharma, Inc., is a biotechnology company. The Company is engaged in developing novel biologics designed for the treatment of chronic skin diseases, including plaque psoriasis. It is advancing a proprietary portfolio of potential antibodies that target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. The Company’s lead programs include ORKA-001 and ORKA-002, which are designed to block cytokines in the pathogenesis of psoriasis and other inflammatory diseases. ORKA-001 is a potentially monoclonal antibody designed to inhibit IL-23p19 for the treatment of psoriasis. ORKA-001 targets the p19 subunit of interleukin-23 (IL-23p19). ORKA-002 is a potentially monoclonal antibody designed to inhibit IL-17A/F for the treatment of psoriasis, psoriatic arthritis, and other conditions. ORKA-002 targets interleukin-17A and interleukin-17F (IL-17A/F).
- Revenue in USD (TTM)0.00
- Net income in USD-7.20m
- Incorporated2004
- Employees4.00
- LocationOruka Therapeutics Inc10170 Church Ranch Way, Suite 100WESTMINSTER 80021United StatesUSA
- Phone+1 (720) 940-2200
- Fax+1 (302) 655-5049
- Websitehttps://orukatx.com/
More ▼
Mergers & acquisitions
| Acquired company | ORKA:NMQ since announced | Transaction value |
|---|---|---|
| Oruka Therapeutics Inc | 45.03% | -- |
Data delayed at least 15 minutes, as of Oct 18 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rapport Therapeutics Inc | 0.00 | -63.02m | 949.16m | 58.00 | -- | 2.82 | -- | -- | -1.76 | -1.76 | 0.00 | 9.21 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -226.57 | -- | -- | -- |
| Zymeworks Inc | 62.71m | -112.51m | 957.72m | 290.00 | -- | 2.37 | -- | 15.27 | -1.52 | -1.52 | 0.8531 | 5.69 | 0.1122 | -- | 1.55 | 230,533.10 | -20.13 | -22.58 | -23.21 | -26.90 | -- | -- | -179.42 | -91.17 | -- | -- | 0.00008 | -- | -81.57 | 7.47 | -195.44 | -- | 3.58 | -- |
| Cullinan Therapeutics Inc | 0.00 | -142.16m | 972.27m | 85.00 | -- | 1.48 | -- | -- | -3.10 | -3.10 | 0.00 | 11.34 | 0.00 | -- | -- | 0.00 | -23.96 | -12.37 | -24.85 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
| Arrivent Biopharma Inc | 0.00 | -74.89m | 979.36m | 40.00 | -- | 3.29 | -- | -- | -2.46 | -2.46 | 0.00 | 8.85 | 0.00 | -- | -- | 0.00 | -29.50 | -- | -31.02 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.86 | -- | -- | -- |
| IGM Biosciences Inc | 2.91m | -220.40m | 991.81m | 204.00 | -- | 8.09 | -- | 340.71 | -3.67 | -3.67 | 0.0485 | 2.07 | 0.0071 | -- | -- | 12,995.54 | -53.94 | -44.66 | -59.96 | -48.20 | -- | -- | -7,571.35 | -23,668.96 | -- | -- | 0.00 | -- | 99.25 | -- | -11.45 | -- | 73.48 | -- |
| Aurinia Pharmaceuticals Inc | 207.11m | -50.35m | 1.01bn | 300.00 | -- | 2.76 | -- | 4.85 | -0.3508 | -0.3508 | 1.44 | 2.55 | 0.3862 | 0.8006 | 9.20 | 690,350.00 | -9.39 | -25.97 | -10.78 | -28.24 | 86.08 | -- | -24.31 | -137.64 | 4.82 | -- | 0.1778 | -- | 30.95 | 227.90 | 27.88 | -- | 57.11 | -- |
| Arcutis Biotherapeutics Inc | 132.06m | -198.76m | 1.02bn | 296.00 | -- | 5.45 | -- | 7.72 | -2.18 | -2.18 | 1.36 | 1.60 | 0.3451 | 0.8334 | 4.36 | 446,155.40 | -51.93 | -65.64 | -58.68 | -71.72 | 92.32 | -- | -150.51 | -1,513.03 | 8.19 | -5.94 | 0.5223 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
| CARGO Therapeutics Inc | 0.00 | -147.71m | 1.02bn | 116.00 | -- | 2.34 | -- | -- | -3.47 | -3.47 | 0.00 | 9.51 | 0.00 | -- | -- | 0.00 | -53.66 | -- | -59.56 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
| Applied Therapeutics Inc | -333.00k | -161.09m | 1.03bn | 31.00 | -- | 14.21 | -- | -- | -1.52 | -1.52 | -0.0029 | 0.6303 | -0.0039 | -- | -- | -13,320.00 | -187.94 | -140.37 | -467.74 | -240.93 | -- | -- | -- | -4,476.42 | -- | -- | 0.00 | -- | -- | -- | -45.15 | -- | -- | -- |
| Oruka Therapeutics Inc | 0.00 | -7.20m | 1.04bn | 4.00 | -- | 1.10 | -- | -- | -5.97 | -5.97 | 0.00 | 26.94 | 0.00 | -- | -- | 0.00 | -19.22 | -27.78 | -19.99 | -29.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 46.21 | -- | -- | -- |
| Vir Biotechnology Inc | 78.88m | -483.04m | 1.04bn | 587.00 | -- | 0.7269 | -- | 13.22 | -3.58 | -3.58 | 0.5838 | 10.50 | 0.0403 | -- | -- | 134,373.10 | -24.69 | -0.6081 | -26.90 | -0.7192 | 98.80 | -- | -612.40 | -1.53 | -- | -- | 0.00 | -- | -94.67 | 51.87 | -219.24 | -- | 16.77 | -- |
| AnaptysBio Inc | 30.47m | -170.12m | 1.06bn | 117.00 | -- | 97.14 | -- | 34.65 | -6.34 | -6.34 | 1.14 | 0.3601 | 0.0645 | -- | 5.00 | 260,453.00 | -36.02 | -18.08 | -39.45 | -18.96 | -- | -- | -558.25 | -269.21 | -- | -- | 0.00 | -- | 66.78 | 27.97 | -27.11 | -- | -5.36 | -- |
| Bicara Therapeutics Inc | 0.00 | -64.84m | 1.08bn | 32.00 | -- | -- | -- | -- | -1.25 | -1.25 | 0.00 | 3.72 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -37.36 | -- | -- | -- |
| Relay Therapeutics Inc | 35.21m | -322.83m | 1.09bn | 304.00 | -- | 1.32 | -- | 30.95 | -2.52 | -2.52 | 0.277 | 5.11 | 0.0406 | -- | -- | 109,003.10 | -37.22 | -28.55 | -39.91 | -29.54 | -- | -- | -916.92 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
Data as of Oct 18 2024. Currency figures normalised to Oruka Therapeutics Inc's reporting currency: US Dollar USD
115.21%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Cable Car Capital LLCas of 30 Jun 2024 | 333.37k | 27.58% |
| Fairmount Funds Management LLCas of 11 Sep 2024 | 266.59k | 22.05% |
| Janus Henderson Investors UK Ltd.as of 16 Aug 2024 | 176.43k | 14.59% |
| RTW Investments LPas of 30 Jun 2024 | 116.67k | 9.65% |
| Janus Henderson Investors US LLCas of 30 Jun 2024 | 115.23k | 9.53% |
| Adage Capital Management LPas of 30 Jun 2024 | 100.00k | 8.27% |
| Allostery Investments LPas of 15 Apr 2024 | 88.75k | 7.34% |
| Avidity Partners Management LPas of 30 Jun 2024 | 83.33k | 6.89% |
| TD Securities (USA) LLCas of 30 Jun 2024 | 58.33k | 4.83% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 54.17k | 4.48% |
More ▼
Data from 17 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
